Related references
Note: Only part of the references are listed.The ATS/ERS/JRS/ALAT statement IPF by HRCT could predict acute exacerbation of interstitial lung disease in non-small cell lung cancer
Nobuhiro Asai et al.
TUMORI (2017)
The ATS/ERS/JRS/ALAT statement IPF by HRCT could predict acute exacerbation of interstitial lung disease in non-small cell lung cancer
Nobuhiro Asai et al.
TUMORI (2017)
Acute Exacerbation of Idiopathic Pulmonary Fibrosis An International Working Group Report
Harold R. Collard et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study
Akimasa Sekine et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer
Yasunori Enomoto et al.
LUNG CANCER (2016)
Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease
Hirotsugu Kenmotsu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
The Efficacy and Safety of Chemotherapy in Patients With Nonsmall Cell Lung Cancer and Interstitial Lung Disease A PRISMA-Compliant Bayesian Meta-Analysis and Systematic Review
Yu Jie Chen et al.
MEDICINE (2015)
A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
Brett Ley et al.
ANNALS OF INTERNAL MEDICINE (2012)
Association of Computed Tomography-detected Pulmonary Interstitial Changes with Severe Radiation Pneumonitis for Patients Treated with Thoracic Radiotherapy
Naoko Sanuki et al.
JOURNAL OF RADIATION RESEARCH (2012)
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
J. W. Song et al.
EUROPEAN RESPIRATORY JOURNAL (2011)
The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer
Hirotsugu Kenmotsu et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias
Yuji Minegishi et al.
LUNG CANCER (2011)
Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti-cancer therapy
Kazutoshi Isobe et al.
RESPIROLOGY (2010)
Exacerbation of Idiopathic Interstitial Pneumonias Associated with Lung Cancer Therapy
Yuji Minegishi et al.
INTERNAL MEDICINE (2009)
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
Y. Ohe et al.
ANNALS OF ONCOLOGY (2007)
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis
A Azuma et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer
Y Ohe et al.
EUROPEAN JOURNAL OF CANCER (2001)
Share Paper
